The Efficiency and Toxicity Of Anlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study

CONCLUSION: The combination of anlotinib and EC-T chemotherapy demonstrated tolerable side effects in the neoadjuvant treatment of early TNBC. pCR was higher than what has been reported in previous clinical studies of chemotherapy alone. This study provides additional rationale for using anlotinib plus docetaxel-epirubicin-based chemotherapy regimen in patients with early-stage TNBCs.PMID:38670862 | DOI:10.1016/j.clbc.2024.01.018

Source: Clinical Breast Cancer - April 26, 2024 Category: Cancer & Oncology Authors: Xi Chen Xinyu Wei Peizhuo Yao Yanbin Liu Haitao Guan Huafeng Kang Di Liu Yan Diao Xiaobin Ma Weili Min Changyou Shan Yang Zhao Fang Zhao Yuanyuan Chen Dong Xiao Qing She Youhuai Liu Yinbin Zhang Shuqun Zhang Source Type: research